• News
  • SAN DIEGO
  • BioTech

Neurelis reclaims rights to epilepsy drug from Biotie

Encinitas-based Neurelis Inc. entered an agreement with Biotie Therapies Corp. to end the option held by Biotie to purchase Neurelis, clearing the way for Neurelis to commence further development of intranasal diazepam (NRL-1) for pediatric and adult epilepsy patients who experience acute repetitive seizures.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments
Subscribe Today!